1016 related articles for article (PubMed ID: 28334423)
1. Are there patients with T1 to T2, lymph node-negative breast cancer who are "high-risk" for locoregional disease recurrence?
Mamtani A; Patil S; Stempel MM; Morrow M
Cancer; 2017 Jul; 123(14):2626-2633. PubMed ID: 28334423
[TBL] [Abstract][Full Text] [Related]
2. Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy.
Truong PT; Olivotto IA; Kader HA; Panades M; Speers CH; Berthelet E
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1337-47. PubMed ID: 15817335
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
5. Selection criteria for postmastectomy radiotherapy in t1-t2 tumors with 1 to 3 positive lymph nodes.
Moo TA; McMillan R; Lee M; Stempel M; Patil S; Ho A; El-Tamer M
Ann Surg Oncol; 2013 Oct; 20(10):3169-74. PubMed ID: 23975289
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic features predicting involvement of non- sentinel axillary lymph nodes in Iranian women with breast cancer.
Moosavi SA; Abdirad A; Omranipour R; Hadji M; Razavi AE; Najafi M
Asian Pac J Cancer Prev; 2014; 15(17):7049-54. PubMed ID: 25227789
[TBL] [Abstract][Full Text] [Related]
7. Impact of postmastectomy radiation on locoregional recurrence in breast cancer patients with 1-3 positive lymph nodes treated with modern systemic therapy.
Tendulkar RD; Rehman S; Shukla ME; Reddy CA; Moore H; Budd GT; Dietz J; Crowe JP; Macklis R
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e577-81. PubMed ID: 22560546
[TBL] [Abstract][Full Text] [Related]
8. Axillary Micrometastases and Isolated Tumor Cells Are Not an Indication for Post-mastectomy Radiotherapy in Stage 1 and 2 Breast Cancer.
Mamtani A; Patil S; Stempel M; Morrow M
Ann Surg Oncol; 2017 Aug; 24(8):2182-2188. PubMed ID: 28429197
[TBL] [Abstract][Full Text] [Related]
9. Locoregional Recurrence Risk for Postmastectomy Breast Cancer Patients With T1-2 and One to Three Positive Lymph Nodes Receiving Modern Systemic Treatment Without Radiotherapy.
Lai SF; Chen YH; Kuo WH; Lien HC; Wang MY; Lu YS; Lo C; Kuo SH; Cheng AL; Huang CS
Ann Surg Oncol; 2016 Nov; 23(12):3860-3869. PubMed ID: 27436202
[TBL] [Abstract][Full Text] [Related]
10. Minimal impact of postmastectomy radiation therapy on locoregional recurrence for breast cancer patients with 1 to 3 positive lymph nodes in the modern treatment era.
Miyashita M; Tada H; Suzuki A; Watanabe G; Hirakawa H; Amari M; Kakugawa Y; Kawai M; Furuta A; Sato K; Yoshida R; Ebata A; Sasano H; Jingu K; Ohuchi N; Ishida T
Surg Oncol; 2017 Jun; 26(2):163-170. PubMed ID: 28577722
[TBL] [Abstract][Full Text] [Related]
11. The clinical value of adjuvant radiotherapy in patients with early stage breast cancer with 1 to 3 positive lymph nodes after mastectomy.
Wu SG; He ZY; Li FY; Wang JJ; Guo J; Lin Q; Guan XX
Chin J Cancer; 2010 Jul; 29(7):668-76. PubMed ID: 20591219
[TBL] [Abstract][Full Text] [Related]
12. Use of Postmastectomy Radiotherapy and Survival Rates for Breast Cancer Patients with T1-T2 and One to Three Positive Lymph Nodes.
Huo D; Hou N; Jaskowiak N; Winchester DJ; Winchester DP; Yao K
Ann Surg Oncol; 2015 Dec; 22(13):4295-304. PubMed ID: 25820998
[TBL] [Abstract][Full Text] [Related]
13. Postmastectomy radiotherapy improves disease-free survival of high risk of locoregional recurrence breast cancer patients with T1-2 and 1 to 3 positive nodes.
He ZY; Wu SG; Zhou J; Li FY; Lin Q; Lin HX; Sun JY
PLoS One; 2015; 10(3):e0119105. PubMed ID: 25781605
[TBL] [Abstract][Full Text] [Related]
14. Locoregional recurrence risk for patients with T1,2 breast cancer with 1-3 positive lymph nodes treated with mastectomy and systemic treatment.
McBride A; Allen P; Woodward W; Kim M; Kuerer HM; Drinka EK; Sahin A; Strom EA; Buzdar A; Valero V; Hortobagyi GN; Hunt KK; Buchholz TA
Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):392-8. PubMed ID: 24721590
[TBL] [Abstract][Full Text] [Related]
15. Patterns and risk factors of locoregional recurrence in T1-T2 node negative breast cancer patients treated with mastectomy: implications for postmastectomy radiotherapy.
Abi-Raad R; Boutrus R; Wang R; Niemierko A; Macdonald S; Smith B; Taghian AG
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e151-7. PubMed ID: 21420245
[TBL] [Abstract][Full Text] [Related]
16. Axillary lymph node recurrence after sentinel lymph node biopsy performed using a combination of indocyanine green fluorescence and the blue dye method in early breast cancer.
Inoue T; Nishi T; Nakano Y; Nishimae A; Sawai Y; Yamasaki M; Inaji H
Breast Cancer; 2016 Mar; 23(2):295-300. PubMed ID: 25348937
[TBL] [Abstract][Full Text] [Related]
17. Survival benefit of post-mastectomy radiotherapy in breast carcinoma patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasis.
Duraker N; Demir D; Bati B; Yilmaz BD; Bati Y; Çaynak ZC; Sobutay E
Jpn J Clin Oncol; 2012 Jul; 42(7):601-8. PubMed ID: 22511807
[TBL] [Abstract][Full Text] [Related]
18. Most Breast Cancer Patients with T1-2 Tumors and One to Three Positive Lymph Nodes Do Not Need Postmastectomy Radiotherapy.
Muhsen S; Moo TA; Patil S; Stempel M; Powell S; Morrow M; El-Tamer M
Ann Surg Oncol; 2018 Jul; 25(7):1912-1920. PubMed ID: 29564588
[TBL] [Abstract][Full Text] [Related]
19. Analysis in early stage triple-negative breast cancer treated with mastectomy without adjuvant radiotherapy: patterns of failure and prognostic factors.
Chen X; Yu X; Chen J; Zhang Z; Tuan J; Shao Z; Guo X; Feng Y
Cancer; 2013 Jul; 119(13):2366-74. PubMed ID: 23576181
[TBL] [Abstract][Full Text] [Related]
20. Predictors of locoregional outcome in HER2-overexpressing breast cancer treated with neoadjuvant chemotherapy.
Arsenault D; Hurley J; Takita C; Reis IM; Zhao W; Rodgers S; Wright JL
Am J Clin Oncol; 2015 Aug; 38(4):348-52. PubMed ID: 23799288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
